Suppr超能文献

炎症和 Hras 信号通路在皮肤肿瘤进展过程中控制上皮间质转化。

Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression.

机构信息

Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94158, USA.

出版信息

Genes Dev. 2013 Mar 15;27(6):670-82. doi: 10.1101/gad.210427.112.

Abstract

Epithelial-mesenchymal transition (EMT) is thought to be an important, possibly essential, component of the process of tumor dissemination and metastasis. About 20%-30% of Hras mutant mouse skin carcinomas induced by chemical initiation/promotion protocols have undergone EMT. Reduced exposure to TPA-induced chronic inflammation causes a dramatic reduction in classical papillomas and squamous cell carcinomas (SCCs), but the mice still develop highly invasive carcinomas with EMT properties, reduced levels of Hras and Egfr signaling, and frequent Ink4/Arf deletions. Deletion of Hras from the mouse germline also leads to a strong reduction in squamous tumor development, but tumors now acquire activating Kras mutations and exhibit more aggressive metastatic properties. We propose that invasive carcinomas can arise by different genetic and biological routes dependent on exposure to chronic inflammation and possibly from different target cell populations within the skin. Our data have implications for the use of inhibitors of inflammation or of Ras/Egfr pathway signaling for prevention or treatment of invasive cancers.

摘要

上皮-间充质转化(EMT)被认为是肿瘤扩散和转移过程中的一个重要(可能是必需的)组成部分。大约 20%-30%的经化学起始/促进方案诱导的 Hras 突变鼠皮肤癌经历了 EMT。TPA 诱导的慢性炎症接触减少导致经典的乳头瘤和鳞状细胞癌(SCC)显著减少,但小鼠仍然发展出具有 EMT 特性的高度侵袭性癌,Hras 和 Egfr 信号水平降低,以及频繁的 Ink4/Arf 缺失。从鼠种系中删除 Hras 也会导致鳞状肿瘤的强烈减少,但肿瘤现在获得了激活的 Kras 突变,并表现出更具侵袭性的转移性特征。我们提出,侵袭性癌可以通过不同的遗传和生物学途径产生,这取决于对慢性炎症的暴露,并且可能来自皮肤内的不同靶细胞群体。我们的数据对使用炎症抑制剂或 Ras/Egfr 通路信号抑制剂预防或治疗侵袭性癌症具有重要意义。

相似文献

2
Mutant Nrf2 enhances the promotion and progression of a subset of oncogenic Ras keratinocytes and skin tumors.
Redox Biol. 2024 Sep;75:103261. doi: 10.1016/j.redox.2024.103261. Epub 2024 Jun 28.
4
Epithelial stem cell mutations that promote squamous cell carcinoma metastasis.
J Clin Invest. 2013 Oct;123(10):4390-404. doi: 10.1172/JCI65856. Epub 2013 Sep 3.
5
Expression of Hras-p21 and keratin K13 in UVR-induced skin tumors in Sencar mice.
J Toxicol Environ Health A. 1998 Mar 27;53(6):439-53. doi: 10.1080/009841098159178.
6
EMT-induced stemness and tumorigenicity are fueled by the EGFR/Ras pathway.
PLoS One. 2013 Aug 12;8(8):e70427. doi: 10.1371/journal.pone.0070427. eCollection 2013.
7
Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
Oncogene. 2013 Aug 22;32(34):4028-33. doi: 10.1038/onc.2012.404. Epub 2012 Sep 3.
8
MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis.
Sci Signal. 2016 Jun 21;9(433):ra62. doi: 10.1126/scisignal.aaf5106.
9
Context Dependency of Epithelial-to-Mesenchymal Transition for Metastasis.
Cell Rep. 2019 Nov 5;29(6):1458-1468.e3. doi: 10.1016/j.celrep.2019.09.081.
10
Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes.
PLoS One. 2022 Mar 24;17(3):e0266017. doi: 10.1371/journal.pone.0266017. eCollection 2022.

引用本文的文献

2
Tumor cell heterogeneity drives spatial organization of the intratumoral immune response.
J Exp Med. 2025 Jun 2;222(6). doi: 10.1084/jem.20242282. Epub 2025 Apr 1.
3
Advances in cutaneous squamous cell carcinoma.
Nat Rev Cancer. 2023 Jul;23(7):430-449. doi: 10.1038/s41568-023-00583-5. Epub 2023 Jun 7.
4
Dissecting metastasis using preclinical models and methods.
Nat Rev Cancer. 2023 Jun;23(6):391-407. doi: 10.1038/s41568-023-00568-4. Epub 2023 May 3.
5
Oh, the Mutations You'll Acquire! A Systematic Overview of Cutaneous Squamous Cell Carcinoma.
Cell Physiol Biochem. 2021 Sep 22;55(S2):89-119. doi: 10.33594/000000433.
7
Pathogenesis and characteristics of large ameloblastoma of the jaw: a report of two rare cases.
J Int Med Res. 2021 May;49(5):3000605211014803. doi: 10.1177/03000605211014803.
9
A RAC-GEF network critical for early intestinal tumourigenesis.
Nat Commun. 2021 Jan 4;12(1):56. doi: 10.1038/s41467-020-20255-4.
10
Cutaneous Squamous Cell Carcinoma: From Biology to Therapy.
Int J Mol Sci. 2020 Apr 22;21(8):2956. doi: 10.3390/ijms21082956.

本文引用的文献

1
Skin squamous cell carcinoma propagating cells increase with tumour progression and invasiveness.
EMBO J. 2012 Dec 12;31(24):4563-75. doi: 10.1038/emboj.2012.312. Epub 2012 Nov 27.
2
Comprehensive genomic characterization of squamous cell lung cancers.
Nature. 2012 Sep 27;489(7417):519-25. doi: 10.1038/nature11404. Epub 2012 Sep 9.
3
MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Cancer Res. 2012 Jun 15;72(12):3048-59. doi: 10.1158/0008-5472.CAN-11-3649. Epub 2012 Apr 17.
4
Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling.
Nat Cell Biol. 2012 Mar 4;14(4):401-8. doi: 10.1038/ncb2464.
6
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
N Engl J Med. 2012 Jan 19;366(3):207-15. doi: 10.1056/NEJMoa1105358.
7
Cancer-related inflammation: common themes and therapeutic opportunities.
Semin Cancer Biol. 2012 Feb;22(1):33-40. doi: 10.1016/j.semcancer.2011.12.005. Epub 2011 Dec 24.
9
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Clin Cancer Res. 2012 Jan 1;18(1):263-72. doi: 10.1158/1078-0432.CCR-11-1344. Epub 2011 Nov 17.
10
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
J Clin Oncol. 2012 Jan 20;30(3):316-21. doi: 10.1200/JCO.2011.36.7680. Epub 2011 Nov 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验